What is Dermata Therapeutics, Inc. (DRMA)?

Dermata Therapeutics, Inc. (DRMA) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of DRMA?

The current price of DRMA is $0.76. Prices are updated in real time on Stocks360.

What is DRMA's price-to-earnings (PE) ratio?

DRMA's trailing twelve-month PE ratio is -0.17, based on current price and earnings per share data available on Stocks360.

What is DRMA's market capitalization?

DRMA's market capitalization is $3,741,181.00, placing it in the small-cap tier.

Dermata Therapeutics, Inc. (DRMA)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.76

Market Cap

$3.74M

PE (TTM)

-0.17

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.66

Day Range

$0.67 – $0.77

52-wk Range

$0.60 – $4.66

Avg Volume

N/A

Volume

186.89K

Dermata Therapeutics, Inc. (DRMA) is a publicly traded company in the Healthcare sector. Latest price: $0.76. Market cap $3.74M. Trailing PE -0.17. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 8 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-28 · $3.76 2026-10-27 · $0.76 (-79.92%)

Earnings

Next Earnings

Nov 18, 2026

EPS estimate $-0.55

Proprietary Signals

Signal snapshot temporarily unavailable.

About Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.17×
P/S (TTM)	0.00×
P/B	0.87×
P/FCF (TTM)	-0.46×
EV / EBITDA	0.08×
EV / Sales	0.00×
Earnings Yield	-275.58%
Free Cash Flow Yield	-217.71%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$671.58K
Net Income (TTM)	-$10.31M
Free Cash Flow (TTM)	-$8.14M
Net Debt	-$4.41M
Working Capital	$3.32M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-166.67%
Return on Invested Capital	-246.61%